Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
60 hedge funds and large institutions have $268M invested in Alpine Immune Sciences Inc in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 25 increasing their positions, 13 reducing their positions, and 8 closing their positions.
92% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 13
7% more capital invested
Capital invested by funds: $251M → $268M (+$16.9M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less funds holding
Funds holding: 62 → 60 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$2.32M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$1.59M |
| 3 |
BlackRock
New York
|
+$925K |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$821K |
| 5 |
HS
HighVista Strategies
Boston,
Massachusetts
|
+$719K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$2.21M |
| 2 |
CCMU
Cheyne Capital Management (UK)
London,
United Kingdom
|
-$1.34M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$308K |
| 4 |
PVI
Pura Vida Investments
New York
|
-$227K |
| 5 |
Two Sigma Advisers
New York
|
-$193K |
ALPN Hedge Fund Activity: Q1 2023 in Review
60 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q1 2023, worth a combined $268M — up 6.7% from $251M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ALPN and 6 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 25 added.
The largest buyer was RA Capital Management, adding an estimated $2.32M. The largest seller was BVF Inc, cutting an estimated $2.21M.
- 60 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q1 2023, down from 62 in Q4 2022.
- Funds reported $268M of Alpine Immune Sciences Inc stock for Q1 2023, up 6.7% quarter-over-quarter.
- 6 funds opened new Alpine Immune Sciences Inc positions in Q1 2023 and 8 closed out, a net change of -2 holders.
- The largest Alpine Immune Sciences Inc buyer in Q1 2023 was RA Capital Management, an estimated $2.32M added.
- The largest Alpine Immune Sciences Inc seller in Q1 2023 was BVF Inc, an estimated $2.21M sold.
Based on aggregated 13F filings for Q1 2023.